Citigroup Inc Atai Life Sciences N.V. Transaction History
Citigroup Inc
- $217 Billion
- Q3 2025
A detailed history of Citigroup Inc transactions in Atai Life Sciences N.V. stock. As of the latest transaction made, Citigroup Inc holds 64,177 shares of ATAI stock, worth $265,051. This represents 0.0% of its overall portfolio holdings.
Number of Shares
64,177
Previous 4,763
1247.41%
Holding current value
$265,051
Previous $10,000
3290.0%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding ATAI
# of Institutions
141Shares Held
38.9MCall Options Held
1.74MPut Options Held
525K-
Ubs Group Ag7.68MShares$31.7 Million0.01% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA5.43MShares$22.4 Million0.05% of portfolio
-
Morgan Stanley New York, NY4.82MShares$19.9 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl2.02MShares$8.34 Million0.07% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD1.94MShares$8.01 Million0.01% of portfolio
About ATAI Life Sciences N.V.
- Ticker ATAI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 165,875,008
- Market Cap $685M
- Description
- Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment o...